TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW
PRESS RELEASES

Citius Holds Webinar Series On Conducting Mino-Lok Phase 3 Trial During COVID-19

  • By PR Newswire
  • Dec 15, 2020 9:40 AM EST
PRESS RELEASES

Citius Pharmaceuticals Receives FDA Response And Guidance To Pre-IND Consultation Submission For Mino-Wrap

  • By PR Newswire
  • Dec 9, 2020 9:40 AM EST
PRESS RELEASES

Citius Pharmaceuticals Subsidiary NoveCite Announces Data From A Study Of Induced Mesenchymal Stem Cell ("i-MSC") Therapy In An In Vivo Model Of Acute Respiratory Distress Syndrome ("ARDS")

  • By PR Newswire
  • Dec 8, 2020 9:15 AM EST
PRESS RELEASES

Citius Pharmaceuticals To Present Corporate Update At Benzinga Global Small Cap Conference On December 8

  • By PR Newswire
  • Dec 3, 2020 3:30 PM EST
PRESS RELEASES

Citius Announces Results Of Study That Mino-Lok Eradicates S. Aureus Biofilm More Effectively And Expeditiously Than Components

  • By PR Newswire
  • Nov 30, 2020 9:15 AM EST
PRESS RELEASES

Citius Pharmaceuticals To Present At Virtual Fall Investor Summit

  • By PR Newswire
  • Nov 10, 2020 9:30 AM EST
PRESS RELEASES

Citius Pharmaceuticals To Present At H.C. Wainwright 6th Annual Israel Conference

  • By PR Newswire
  • Nov 9, 2020 9:30 AM EST
PRESS RELEASES

Citius Pharmaceuticals Issues October 2020 Letter To Shareholders

  • By PR Newswire
  • Oct 27, 2020 9:00 AM EDT
PRESS RELEASES

Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) To NoveCite For COVID-19 Related Acute Respiratory Distress Syndrome (ARDS) And Other Acute Respiratory Conditions

  • By PR Newswire
  • Oct 13, 2020 7:30 AM EDT
PRESS RELEASES

Citius's Mino-Lok Trial Sites Resupplied With Registration Batch Product

  • By PR Newswire
  • Sep 30, 2020 9:45 AM EDT
PRESS RELEASES

Citius Pharmaceuticals Reports Positive Results From Recent Data Monitoring Committee Meeting For Mino-Lok Phase 3 Trial

  • By PR Newswire
  • Sep 29, 2020 10:17 AM EDT
PRESS RELEASES

Citius Pharmaceuticals Achieves Chemical Manufacturing And Control Milestones For Mino-LokĀ®

  • By PR Newswire
  • Sep 22, 2020 8:15 AM EDT
PRESS RELEASES

Citius Files Addendum To Mino-Lok Phase 3 Trial Record Keeping Protocol To Advance Trials With COVID-19 Compliance

  • By PR Newswire
  • Sep 15, 2020 10:17 AM EDT
PRESS RELEASES

Citius Pharmaceuticals To Present At H.C. Wainwright Virtual 22nd Annual Global Investment Conference

  • By PR Newswire
  • Sep 8, 2020 10:00 AM EDT
PRESS RELEASES

Citius Pharmaceuticals To Present At The LD 500 Virtual Conference

  • By PR Newswire
  • Aug 27, 2020 9:00 AM EDT
PRESS RELEASES

Citius Pharmaceuticals Announces Improved Design And Expansion Of Intellectual Property For Mino-Wrap

  • By PR Newswire
  • Aug 26, 2020 10:00 AM EDT
PRESS RELEASES

Citius Pharmaceuticals To Present At The MoneyShow Las Vegas Virtual Expo

  • By PR Newswire
  • Aug 13, 2020 9:45 AM EDT
PRESS RELEASES

Citius Pharmaceuticals Announces Closing Of $9.6 Million Bought Deal Offering And Full Exercise Of Underwriter's Option To Purchase Additional Shares

  • By PR Newswire
  • Aug 10, 2020 3:18 PM EDT
PRESS RELEASES

Citius Pharmaceuticals Increases Previously Announced Bought Deal Offering To $8.4 Million

  • By PR Newswire
  • Aug 5, 2020 9:00 PM EDT
PRESS RELEASES

Citius Pharmaceuticals Announces $6.0 Million Bought Deal Offering

  • By PR Newswire
  • Aug 5, 2020 5:32 PM EDT
PRESS RELEASES

Citius Submits Mino-Wrap Briefing Package To FDA For Pre-IND Consult

  • By PR Newswire
  • Aug 4, 2020 8:17 AM EDT
PRESS RELEASES

Citius Pharmaceuticals Forms Scientific Advisory Board For The Planned Development Of Its Proprietary Treatment For Acute Respiratory Disease Associated With COVID-19

  • By PR Newswire
  • Jul 22, 2020 10:30 AM EDT
PRESS RELEASES

Citius Pharmaceuticals To Present At The MoneyShow Accredited Investor Virtual Event

  • By PR Newswire
  • Jul 20, 2020 2:00 PM EDT
PRESS RELEASES

Citius Pharmaceuticals Brings On Myron S. Czuczman, M.D. As Chief Medical Officer (CMO) And Executive Vice President

  • By PR Newswire
  • Jul 14, 2020 8:47 AM EDT
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.